Companies › Tarian Pharma
1 active drug program in 1 registered trial: 1 Phase 2; Immunology.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| TAR-0520 Gel Brimonidine tartrate - selective alpha-2 adrenergic receptor agonist | ADRA2A, ADRA2B, ADRA2C | Phase 2 | EGFR Inhibitor-associated Rash | – |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT06818058 | TAR-0520 Gel | Phase 2 | EGFR Inhibitor-associated Rash | Immunology | Sep 2026 |
Calixis Morphic Therapeutic, Inc. (A Wholly Owned Subsidiary of Eli Lilly and Company) Qifeng Zhang Topadur Pharma Leadingtac Pharmaceutical (Shaoxing)
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.